Headlines about Celldex Therapeutics (NASDAQ:CLDX) have been trending somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Celldex Therapeutics earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.9352546984858 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news headlines that may have effected Accern’s analysis:

Celldex Therapeutics (NASDAQ CLDX) opened at $2.98 on Thursday. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $4.07.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.07. The company had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The business’s quarterly revenue was up 77.3% on a year-over-year basis. During the same period last year, the business earned ($0.29) EPS. equities research analysts anticipate that Celldex Therapeutics will post -0.93 earnings per share for the current year.

A number of research firms recently issued reports on CLDX. HC Wainwright reissued a “buy” rating on shares of Celldex Therapeutics in a research note on Tuesday, November 7th. ValuEngine cut Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. WBB Securities reissued a “buy” rating and set a $10.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, December 6th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $9.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $7.05.

COPYRIGHT VIOLATION WARNING: “Celldex Therapeutics (CLDX) Earning Somewhat Positive Press Coverage, Report Shows” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/12/14/celldex-therapeutics-cldx-earning-somewhat-positive-press-coverage-report-shows.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Insider Buying and Selling by Quarter for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Stock Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related stocks with our FREE daily email newsletter.